Exonhit Therapeutics is categorized under Commercial Biotechnical Research in Gaithersburg, MD and active since 2001.
Exonhit Therapeutics was established in 2001, and today employs 1 to 4, earning Unknown per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 5417110 by the NAICS.
If you are seeking more information, feel free to contact Corinne Hoff, Other at the company’s single location by writing to 217 Perry Parkway # 5, Gaithersburg, Maryland MD 20877 or by phoning (240) 683-7060. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Exonhit Therapeutics |
| Contact Person: | Corinne Hoff, Other |
| Address: | 217 Perry Parkway # 5, Gaithersburg, Maryland 20877 |
| Phone Number: | (240) 683-7060 |
| Website Address: | exonhit.com |
| Annual Revenue (USD): | Unknown |
| Founded: | 2001 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 5417110 |
| Share This Business: |
Exonhit Therapeutics was started in 2001 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 5417110. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of Unknown per annum.
Feel free to contact Corinne Hoff, Other for inquiries that concern Exonhit Therapeutics by calling the company number (240) 683-7060, as your correspondence is most welcome. Additionally, the physical location of the single location of Exonhit Therapeutics can be found at the coordinates 39.14436,-77.21334 as well as the street address 217 Perry Parkway # 5 in Gaithersburg, Maryland 20877.
For its online presence, you may visit Exonhit Therapeutics’s website at exonhit.com and engage with its social media outlets through on Twitter and on Facebook.